Demirkan K, Bozkurt B, Karakaya G, Kalyoncu A F
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
J Investig Allergol Clin Immunol. 2006;16(3):203-9.
Proton pump inhibitors and H2 receptor antagonists, which are commonly used to treat peptic ulcer and gastroesophageal reflux diseases, are associated with a low incidence of adverse reactions. We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period. Cutaneous sensitivity to famotidine, ranitidine, omeprazole, pantoprazole, and lansoprazole was evaluated by skin prick tests with a concentration of 10 mg/mL (at 1:1000, 1:100, 1:10 and 1:1 dilutions), and if they were negative, intradermal skin tests were performed with the same dilutions of the extracts. Single-blind, placebo-controlled oral provocation tests were performed with lansoprazole, omeprazole, famotidine, and ranitidine in 2 cases. One case involved anaphylaxis during an oral provocation test with lansoprazole, and 2 cases were anaphylactic reactions to ranitidine. In both cases the skin test was positive for ranitidine and in 1 case an oral provocation test was also positive. The second patient refused that test. Cross reactivity to other H2 receptor antagonists was not demonstrated and a safe alternative drug was found for all 3 patients. Although incidences of anaphylactic reactions induced by proton pump inhibitors or H2 reactions are rare, they can be life threatening.
质子泵抑制剂和H2受体拮抗剂常用于治疗消化性溃疡和胃食管反流病,其不良反应发生率较低。我们报告了在13年期间,在8304例首诊患者中诊断出的3例由兰索拉唑或雷尼替丁引起的过敏反应。通过浓度为10mg/mL(1:1000、1:100、1:10和1:1稀释度)的皮肤点刺试验评估对法莫替丁、雷尼替丁、奥美拉唑、泮托拉唑和兰索拉唑的皮肤敏感性,如果结果为阴性,则用相同稀释度的提取物进行皮内皮肤试验。对2例患者进行了兰索拉唑、奥美拉唑、法莫替丁和雷尼替丁的单盲、安慰剂对照口服激发试验。1例在口服兰索拉唑激发试验期间发生过敏反应,2例对雷尼替丁发生过敏反应。2例患者的雷尼替丁皮肤试验均为阳性,1例口服激发试验也为阳性。第二例患者拒绝了该试验。未证实对其他H2受体拮抗剂存在交叉反应,并且为所有3例患者找到了安全的替代药物。尽管质子泵抑制剂或H2受体拮抗剂引起的过敏反应发生率很低,但可能危及生命。